Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab - Wikidata - wikimedia - TriplyDB

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

http://www.wikidata.org/entity/Q36862845

about

National consensus in China on diagnosis and treatment of patients with advanced breast cancer Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer Breast cancer brain metastases: biology and new clinical perspectives Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival.A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases Emerging strategies for treating brain metastases from breast cancer.Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models.Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab.Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain.When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease.The future of targeted therapies for brain metastases.Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?Brain metastasis in breast cancer: a comprehensive literature review.The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients.Targeted Treatment of Brain Metastases.Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.Comprehensive molecular biomarker identification in breast cancer brain metastases.Metabolic advantages and vulnerabilities in brain metastases.Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression.Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?Solitary pituitary metastasis from HER2-positive breast cancer.Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer.

P2860

Q26775621-15761266-F8FC-4A68-8519-211BEFEABDE8 Q27003258-3FDC17A9-2A76-434B-8CFB-B707C7CF5C71 Q28078998-01E97153-D45B-45F6-AFA4-F583FF87677F Q33618685-17058C6B-0A7A-4129-9CFD-95A1CEA100A8 Q33739161-E278707A-BE15-471A-8D7C-2746A77D4B94 Q34023704-3016BA4F-B94F-4DFE-A306-ACC1E2583D9D Q34240305-3F045E08-ED7D-45C6-9984-DDE147941DE8 Q35067584-2E44E6F0-7ACE-4670-B333-93DD9962A1B1 Q35075446-2D48A828-3058-4E67-9FE9-BACE668A42C3 Q35186481-281636EE-51B8-4637-9CCF-25DC83F0CA09 Q35948012-17CEC4E2-397F-4FA2-84EE-6CA2F1FAE2D7 Q36544212-546AB671-B0BB-4CE1-A132-07997722F7E5 Q36824869-BAB328BE-A12C-4040-8621-69C50AD2E880 Q37301435-914E7C12-31ED-4AE8-8663-9FFA7BE18C05 Q37480177-C6DD1927-FDEF-484B-B71C-12C4F02B31B1 Q37576694-8A41D3E5-478B-4D0B-BBC7-A209BD5F8152 Q38564085-D20FDE67-A537-4FC9-AB45-D3CA89FB1670 Q38616628-96E60CA5-D5A3-4875-B7FA-E63C5F306F5F Q38748013-0F7C8F05-E277-4865-9591-906E1C9A90C1 Q38766447-7373B521-AE98-4259-9095-9F06A42F62D3 Q38829087-818EF1A1-7BDE-473A-88FE-46E0388DB8F1 Q39036113-D54AE075-F208-41D1-9AA4-C7379B0904D1 Q39192200-0BC77AFE-CC25-4514-AC0D-5CC589CC5576 Q41555316-91F86602-5CF7-4FBF-B46D-FB817DD3013D Q44844636-46AC5E99-D1D3-4D67-B846-62649A8BF62D Q47098306-519D33CD-CF2F-4A80-8B14-6D8BFDC6AB5E Q47566658-360F269F-AFE8-4302-B27D-FBCD742FDD00 Q47839509-7721AB9B-D64A-43C1-9824-195CEF57B31E Q47852200-0E4FC365-8034-4EF9-8E4F-ED8C19513463 Q48404872-77759376-B857-4113-9D1B-63606306D542 Q48614511-1BEE71E9-CDFD-450A-B483-FDA6459E9199 Q48713634-F37F0D3C-E228-49AC-9FB0-937A05F5D8DE Q50043843-25630C15-D3AF-48A8-8A7D-03C4B425452B Q52951863-8A368596-29B9-4BB3-B647-F9E89BC2AEE0 Q54940766-3A128BA5-887F-4FC3-944C-E07F1FE2182F

P2860

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

http://www.wikidata.org/entity/Q36862845

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Incidence and risk of central ...... ated with adjuvant trastuzumab

@en

type

label

Incidence and risk of central ...... ated with adjuvant trastuzumab

@en

prefLabel

Incidence and risk of central ...... ated with adjuvant trastuzumab

@en

P1433

Q36862845-3DC8342D-8E93-4E76-8582-279529D4255C

P1476

Q36862845-78B50B51-9066-4D9E-BBF3-00317BFBA1FF

P2093

Q36862845-071464F8-430E-4A03-A179-900A6FA7046D

Q36862845-412F570D-F75E-4BFB-8E19-CE41DCAB01A4

Q36862845-6D4C2DEA-4121-407E-8AD6-C57D251F7BF2

Q36862845-B0F80266-04AC-4A9E-B0A2-F4CE0EEFE3CF

Q36862845-D8623218-D6D4-40B5-86B9-ADF05B43594E

P2860

Q36862845-03F9562B-588F-4B8B-ABD7-6B021CABC72B

Q36862845-06A05A02-74FB-4985-97FE-2A63F9EA4166

Q36862845-135D9513-CE02-44A6-8579-47F360E46625

Q36862845-20876B4F-343B-4EAB-AF5E-2DB4171D42DC

Q36862845-2CBFEECE-168F-4889-9E64-94699F0A1598

Q36862845-2F3F4FE4-8B62-495A-A64C-658502BB3DE1

Q36862845-5BDEAEDB-5E51-4F0A-A771-6273FA19377E

Q36862845-5BFA07F6-7DEE-49CB-BD70-3A7D054010B4

Q36862845-617067C0-CA2D-4C19-87CD-6ADDA9C5D110

Q36862845-62304D75-1373-4C09-9412-4837ABF4C0C2

P304

Q36862845-9BF24172-3389-406E-9E37-18539A529552

P31

Q36862845-0343fce9-9cfc-4c2f-b9b4-f5e0131c4b83

Q36862845-1755393E-8284-4E32-8EF7-648BA4515A45

P356

Q36862845-E00803AC-1DA1-4DDD-A84B-DB3308238E85

P433

Q36862845-D75FDB21-A5D0-4FBF-95D2-D17CE9AB8D35

P478

Q36862845-8DE0288B-2CE8-4232-A697-FA5B4949F9F2

P50

Q36862845-2188E410-06F7-43B1-8627-E87FF0AF07FE

P577

Q36862845-BE20CF64-4DF9-44E7-869B-CC7AC37EC6CA

P5875

Q36862845-8CBC9FC8-7BFB-40B6-B305-4179476DB287

P698

Q36862845-F8C98926-2981-415C-87FE-34420B6C2E04

P932

Q36862845-29C0F8DB-B3C0-4C6E-A0E5-76CDA103073B

P356

P1433

Annals of Oncology

P1476

Incidence and risk of central ...... ated with adjuvant trastuzumab

@en

P2093

C L Shapiro

http://www.w3.org/2001/XMLSchema#string

C S Wu

http://www.w3.org/2001/XMLSchema#string

E M Olson

http://www.w3.org/2001/XMLSchema#string

J Maly

http://www.w3.org/2001/XMLSchema#string

N U Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Operating characteristics of a rank correlation test for publication bias

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Prophylactic cranial irradiation in extensive small-cell lung cancer.

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

P304

1526-1533

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDT036

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Mahmoud Abdel-Rasoul

P577

2013-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235797692

http://www.w3.org/2001/XMLSchema#string

P698

23463626

http://www.w3.org/2001/XMLSchema#string

P932

3660080

http://www.w3.org/2001/XMLSchema#string